Patents by Inventor Klaus G. Klumpp

Klaus G. Klumpp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
    Publication number: 20210369755
    Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
    Type: Application
    Filed: February 12, 2021
    Publication date: December 2, 2021
    Inventors: Mark SMITH, Klaus G. KLUMPP
  • 4?-fluoro-2?-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 10953030
    Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: March 23, 2021
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
    Publication number: 20200197431
    Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
    Type: Application
    Filed: August 5, 2019
    Publication date: June 25, 2020
    Inventors: Mark SMITH, Klaus G. KLUMPP
  • 4?-fluoro-2?-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 10682369
    Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: June 16, 2020
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
    Publication number: 20190231804
    Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 1, 2019
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4?-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication
    Patent number: 10358458
    Abstract: The application discloses compounds of Formula I wherein the variable substituents are as defined herein. The compounds of Formula I and pharmaceutical compositions comprising compounds of Formula I are useful for the treatment of diseases mediated by RSV.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: July 23, 2019
    Assignee: RIBOSCIENCE LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4?-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication
    Patent number: 10092649
    Abstract: The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: October 9, 2018
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
    Publication number: 20180200280
    Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
    Type: Application
    Filed: September 21, 2017
    Publication date: July 19, 2018
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4?-fluoro-2?-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 9895442
    Abstract: The present disclosure relates to the compound of Formula I: Also disclosed are pharmaceutical compositions comprising the compound of Formula I, methods of using the compound of Formula I and/or compositions comprising the compound of Formula I for the treatment of HCV.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: February 20, 2018
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication
    Publication number: 20170296664
    Abstract: The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: June 20, 2016
    Publication date: October 19, 2017
    Inventors: Mark Smith, Klaus G. Klumpp
  • Inhibitors of Zika Virus
    Publication number: 20170232031
    Abstract: The application provides methods for treatment or prophylaxis of Zika Virus mediated diseases with compounds of Formula I wherein the variables R1, R2, R3, R4, R5, and Base are defined as described hereinabove.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 17, 2017
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4?-azido, 3?-deoxy-3?-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 9694028
    Abstract: The present disclosure relates to the compound of Formula I: Also disclosed are pharmaceutical compositions comprising the compound of Formula I, methods of using the compound of Formula I and/or compositions comprising the compound of Formula I for the treatment of HCV.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: July 4, 2017
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4'-VINYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS RNA REPLICATION
    Publication number: 20160264611
    Abstract: The application discloses compounds of Formula I wherein the variable substituents are as defined herein. The compounds of Formula I and pharmaceutical compositions comprising compounds of Formula I are useful for the treatment of diseases mediated by RSV.
    Type: Application
    Filed: September 25, 2015
    Publication date: September 15, 2016
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF EBOLA VIRUS RNA REPLICATION
    Publication number: 20160237106
    Abstract: The application discloses compounds of Formula I wherein the variable substituents are as defined herein. The compounds of Formula I and pharmaceutical compositions comprising compounds of Formula I are useful for the treatment of diseases mediated by Filoviruses such as Ebolavirus.
    Type: Application
    Filed: January 13, 2016
    Publication date: August 18, 2016
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
    Publication number: 20160220596
    Abstract: The present disclosure relates to the compound of Formula I: Also disclosed are pharmaceutical compositions comprising the compound of Formula I, methods of using the compound of Formula I and/or compositions comprising the compound of Formula I for the treatment of HCV.
    Type: Application
    Filed: February 2, 2016
    Publication date: August 4, 2016
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4?-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication
    Patent number: 9370569
    Abstract: The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 21, 2016
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • Method of Treating Dengue Fever
    Publication number: 20160168186
    Abstract: The application provides methods for treatment or prophylaxis of dengue virus mediated diseases with compounds of Formula I wherein R1, R2a, R2b, R3, R4, R5 R6, R8a, R9 and R10 are as defined herein. The application further discloses methods for treatment or prophylaxis of dengue virus mediated diseases with pharmaceutical compositions comprising compounds of Formula I.
    Type: Application
    Filed: October 9, 2015
    Publication date: June 16, 2016
    Inventors: Hassan Javanbakht, Klaus G. Klumpp, Suping Ren, Zhuming Zhang
  • 4?-azido, 3?-deoxy-3?-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 9249176
    Abstract: The present disclosure relates to the compound of Formula I: Also disclosed are pharmaceutical compositions comprising the compound of Formula I, methods of using the compound of Formula I and/or compositions comprising the compound of Formula I for the treatment of HCV.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: February 2, 2016
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • ANTIVIRAL COMPOUNDS
    Publication number: 20150307461
    Abstract: The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
    Type: Application
    Filed: July 7, 2015
    Publication date: October 29, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joseph A. Bilotta, Zhi Chen, Elbert Chin, Qingjie Ding, Shawn D. Erickson, Stephen D. Gabriel, Klaus G. Klumpp, Han Ma, Eric Mertz, Jean-Marc Plancher, Robert J. Weikert
  • 4'-Difluoromethyl Substituted Nucleoside Derivatives as Inhibitors of Influenza RNA Replication
    Publication number: 20150225441
    Abstract: The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: February 6, 2015
    Publication date: August 13, 2015
    Inventors: Mark Smith, Klaus G. Klumpp